Chimeric Therapeutics Ltd has released a press release.
Chimeric receives $4.5M R&D tax incentive
Filed with ASX ·
6ix hasn’t read this filing yet.
Chimeric Therapeutics Limited on 6ix
In the deck
Earlier from Chimeric Therapeutics
- 75% disease control observed in CHM CDH17 trial
- CHM CORE NK Combination Phase 1b trial update
- Pause in Trading
- Response to ASX Query Letter
- Additional complete responses in CHM CORE-NK Phase 1b trial
Later from Chimeric Therapeutics
- CDH17 granted FDA Orphan Drug Designation for Gastric Cancer
- Trading Halt
- $8.4 M funding to drive CHM CDH17 and resignation of CMO
- Quarterly Activities/Appendix 4C Cash Flow Report
- Funding and EGM update
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics